Lanean...
Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy
BACKGROUND & AIMS: Increasing drug prices lead to payer coverage restrictions, which limit to therapy. We assessed the cost effectiveness of rifaximin in management of patients with irritable bowel syndrome with diarrhea (IBS-D) under common payer coverage restrictions and determined the maximum...
Gorde:
| Argitaratua izan da: | Clin Gastroenterol Hepatol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717682/ https://ncbi.nlm.nih.gov/pubmed/30831219 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2019.02.039 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|